Drug Profile


Alternative Names: KPT-335

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antivirals; Hydrazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Viral infections

Most Recent Events

  • 16 Mar 2017 Karyopharm Therapeutics has patent protection for verdinexor in USA
  • 20 May 2015 Karyopharm Therapeutics announces intention to submit IND to the US FDA in the year 2015
  • 20 May 2015 Karyopharm Therapeutics plans a phase I trial in Healthy volunteers in USA (PO) (NCT02431364)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top